8-K: Personalis Merger HSR Waiting Period Expires

Personalis, Inc. announced the expiration of the HSR waiting period for its proposed merger with Tempus AI, Inc., clearing a significant regulatory hurdle.

Summary

• The Hart-Scott-Rodino (HSR) Act waiting period for the merger between Personalis, Inc. and Tempus AI, Inc. has expired as of October 2, 2026.
• This expiration is a key step towards the consummation of the previously announced merger agreement.
• The merger is still subject to other closing conditions, including the approval of Personalis stockholders.
• Tempus AI filed an amended preliminary Registration Statement on Form S-4 with the SEC on October 2, 2026, which includes a proxy statement and prospectus.
• A virtual meeting for Personalis stockholders to vote on the merger agreement is scheduled for a future date to be announced.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral update, primarily confirming procedural progress on a previously announced merger, with no new financial or strategic information.

Positives

• The expiration of the HSR waiting period signifies regulatory approval and removes a significant obstacle to the merger.
• This progress indicates that the merger is moving forward as planned, subject to remaining conditions.

Negatives

• The merger is still contingent on Personalis stockholder approval, which is not yet secured.
• The filing does not provide updated financial information or details on the strategic integration post-merger.

Risks

• The possibility that Personalis stockholders may not approve the Merger Agreement.
• A risk that a condition to closing of the transaction may not be satisfied (or waived), or that either party may terminate the Merger Agreement.
• The risk that the closing of the transaction might be delayed or not occur at all.
• Potential adverse reactions or changes to business or employee relationships resulting from the announcement or completion of the transaction.
• The diversion of management time on transaction-related issues.
• The response of competitors to the proposed transaction.
• The ultimate timing, outcome, and results of integrating the operations of Tempus and Personalis.
• Operating costs and business disruption may be greater than expected following the public announcement or consummation of the transaction.

Future Outlook

The consummation of the mergers is subject to customary closing conditions, including the expiration or early termination of the HSR waiting period and the receipt of Company Stockholder Approval. A meeting for stockholders to vote on the merger agreement will be held on a date to be determined.

Industry Context

StockSavvy.ai notes that the expiration of the HSR waiting period is a standard procedural step in large mergers, particularly in the competitive and highly regulated biotechnology and healthcare technology sectors where both Personalis and Tempus operate. This clearance suggests no significant antitrust concerns were raised by regulators regarding the combination.

Stakeholder Impact

• Shareholders: The merger's completion will result in Personalis becoming a subsidiary of Tempus, impacting their future investment value and potential returns.
• Employees: Integration of operations may lead to changes in roles, responsibilities, and organizational structure.
• Customers: The combined entity's service offerings and product development strategies may evolve, affecting customer relationships and service delivery.

Next Steps

• Hold the Company Stockholders Meeting to consider and vote on the adoption of the Merger Agreement.
• Satisfy or waive other closing conditions specified in the Merger Agreement.
• Complete the First Merger and the Second Merger.

Key Dates

Keywords

Merger, HSR Act, Regulatory Approval, Antitrust, Stockholder Approval, Form S-4, Proxy Statement, Tempus AI